Open access peer-reviewed chapter

Introductory Chapter: Myelodysplastic Syndromes

By Ota Fuchs

Reviewed: June 27th 2016Published: September 7th 2016

DOI: 10.5772/64729

Downloaded: 1011

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML) [15]. MDS are rare in young people, and median age of patients with MDS is approximately 70 years [6, 7]. Current management in MDS includes supportive care, drug therapy, and allogeneic stem cell transplantation. MDS patients older than age 70 years are not good candidates for allogeneic stem cell transplantation [8, 9]. The major complication of MDS patients after allogeneic stem cell transplantation with reduced intensity conditioning is relapse of malignant disease. Relapse can be predicted by monitoring of Wilms’ tumor 1 (WT1) gene expression by real-time PCR and CD34+ donor chimerism analysis [10].

Single-nucleotide polymorphism array (SNP-A) analysis, standard metaphase cytogenetics, and rapid progress in flow cytometric analysis, genes mutation analysis, and gene expression profiling have identified key deregulated genes and signaling pathways important for accurate prognostication and risk stratification for individual patients with MDS [1118]. The initial French–British–American (FAB) classification system of MDS was published in 1982 [19] and was later refined to the International Prognostic Scoring System (IPSS) [20] and to World Health Organization (WHO) Prognostic Scoring System (WPSS) [21, 22]. The new revised IPSS (IPSS-R) integrated marrow cytogenetic subset, marrow blast percentage, and depth of cytopenias (hemoglobin, platelet, and absolute neutrophil count) and was published in 2012 [23]. Validation of WPSS for MDS and comparison with IPSS-R has been recently described [24]. Two other prognostic systems for MDS subgroups (M.D. Anderson lower risk MDS prognostic scoring system; chronic myelomonocytic leukemia /CMML/ prognostic scoring system) exist [18, 25].

In lower risk MDS, treatment focuses on amelioration of consequences of cytopenias and transfusions and improving of quality of life. The first line of therapy of lower risk MDS with normal chromosome 5 is treatment with erythropoiesis-stimulating agents (erythropoietin) with or without of granulocyte colony-stimulating factor [26]. Transfusion-dependent lower risk MDS patients with del(5q) are treated with immunomodulatory or cereblon-binding drug lenalidomide [27]. Thrombocytopenia occurring sometimes in combination with anemia or without anemia can be treated with romiplostin (thrombopoietin agonist) [27]. Neutropenia is treated with growth factors (G-CSF and GM-CSF) [27]. Higher-risk MDS if untreated have median survival only about 12 months. Two hypomethylating agents (azacitidine and decitabine) inhibit DNA methyltransferases 3A and 3B and reverse the aberrant methylation involved in MDS progression to AML. The development of novel therapeutic strategies in MDS is dependent on recent advances in the molecular pathogenesis of MDS [6, 16, 2839]. Various combination therapies in MDS are also intensively studied [27, 40, 41].

© 2016 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Ota Fuchs (September 7th 2016). Introductory Chapter: Myelodysplastic Syndromes, Myelodysplastic Syndromes, Ota Fuchs, IntechOpen, DOI: 10.5772/64729. Available from:

chapter statistics

1011total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Immune Dysregulation in Myelodysplastic Syndromes: Pathogenetic-Pathophysiologic Aspects and Clinical Consequences

By Argiris Symeonidis and Alexandra Kouraklis-Symeonidis

Related Book

First chapter

Introductory Chapter: Development of Neutrophils and Their Role in Hematopoietic Microenvironment Regulation

By Ota Fuchs

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us